A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation
Latest Information Update: 04 Apr 2025
At a glance
- Drugs JYP 0015 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms STAR
- Sponsors Guangzhou JOYO Pharma
- 04 Apr 2025 New trial record